Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

IO Biotech Q3 EPS $(0.56)

IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.56) per share.

byBill Haddad

November 9, 2022

1 minute read

IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.56) per share.

Truist Securities Maintains Buy on Spirit AeroSystems Hldgs, Lowers Price Target to $60

By Benzinga Newsdesk

Today, 11:42 PM

Truist Securities analyst Michael Ciarmoli maintains Spirit AeroSystems Hldgs (NYSE:SPR) with a Buy and lowers the price target from $70 to $60.

SPR

Copart Late Wednesday Reports Q1 EPS $0.51 Misses $0.56 Estimate, Sales $893.37M Miss $898.80M Estimate

By Benzinga Newsdesk

Today, 11:42 PM

Copart (NASDAQ:CPRT) reported quarterly earnings of $0.51 per share which missed the analyst consensus estimate of $0.56 by 8.93 percent. This is a 52.34 percent decrease over earnings of $1.07 per share from the same

CPRT

India Globalization Capita Just Got FDA Approval To Start Enrolling Their Phase 2 Alzheimer Trial With IGC-AD1, A Cannabis Drug

By Benzinga Newsdesk

Today, 11:42 PM

https://clinicaltrials.gov/ct2/show/NCT05543681 Brief Summary: This is a superiority, parallel group, double blinded, randomized, powered, multi-site, and placebo-controlled study. Ages 60 and above

IGC

Earnings

PTC Therapeutics Earnings Perspective: Return On Capital Employed

By Benzinga Insights

Today, 11:42 PM

According to data from Benzinga Pro, during Q2, PTC Therapeutics's (NASDAQ:PTCT) reported sales totaled $116.68 million. Despite a 0.26% increase in earnings, the company posted a loss of $97.79 million.

PTCT

IO Biotech Q3 EPS $(0.56)

Related Posts

Truist Securities Maintains Buy on Spirit AeroSystems Hldgs, Lowers Price Target to $60

Copart Late Wednesday Reports Q1 EPS $0.51 Misses $0.56 Estimate, Sales $893.37M Miss $898.80M Estimate

India Globalization Capita Just Got FDA Approval To Start Enrolling Their Phase 2 Alzheimer Trial With IGC-AD1, A Cannabis Drug

PTC Therapeutics Earnings Perspective: Return On Capital Employed